🧬 Genetic Test (Inherited Thrombophilia)

Prothrombin Gene Mutation (G20210A): Nursing Guide

Prothrombin G20210A is the second most common inherited thrombophilia: a change in the F2 gene raises prothrombin (factor II) production and lifetime venous thromboembolism risk — especially with pregnancy, surgery, estrogen therapy, immobility, or co-inherited factor V Leiden. Nurses prevent harm by confirming appropriate ordering, avoiding “positive gene equals active clot” language, coordinating genetics or haematology follow-up, and escalating new leg swelling, chest pain, or dyspnoea clinically.

15 min read
Updated June 20, 2026
Medically Reviewed
Written by
Sid A. Abdala Balal
RN — Registered Nurse
Medically Reviewed by
Dr. Adam Sayedi
MD — Medical Doctor

Contents

Overview Safety Note Can / Cannot Safety Check Clinical Interpretation Related Tests Bedside Notes Clarify / Hold Workflow Mental Checklist Why It Is Ordered Patient Preparation Specimen / Procedure Results & Interpretation Clinical urgency & escalation Nursing Responsibilities Documentation Patient Education Prothrombin Gene Mutation (G20210A) NCLEX practice questions FAQ References Related Topics Editorial Review

Quick Facts

Category
Inherited thrombophilia DNA test
Why it is ordered
Recurrent or familial VTE workup
Main nursing risk
Misreading genetics as acute clot or dismissing symptoms
Turnaround
Often days to weeks

Key Takeaway

A positive prothrombin G20210A result raises lifetime clot risk but does not diagnose active DVT or PE today — and many carriers never develop thrombosis.

Gene & Method Details

Nurse quick-reference for specimen routing, consent context, and result handoff.

Gene(s) tested

F2 (prothrombin / coagulation factor II) — G20210A (20210G>A) variant

Test method

DNA genotyping (PCR, allele-specific amplification, or sequencing) — specific platform varies by laboratory

Specimen

Peripheral blood (EDTA) or approved saliva/buccal kit

Inheritance pattern

Autosomal dominant (germline)

Turnaround

Commonly days to several weeks depending on referral laboratory — not specified as a single universal turnaround in the published references

Germline / somatic

Germline (inherited) thrombophilia testing

Genetic counselling

Recommended when results may change anticoagulation duration, hormone choices, or family screening per institutional genetics or haematology policy

What is Prothrombin Gene Mutation (G20210A)?

Prothrombin Gene Mutation (G20210A) detects the prothrombin G20210A variant (also written 20210G>A or c.*97G>A) in the F2 gene. Prothrombin is a clotting protein converted to thrombin, which drives fibrin clot formation. The G20210A change increases prothrombin production, raising thrombin generation and clot tendency. Testing is performed by DNA analysis on blood or an approved saliva specimen.

Overview

Nurses support prothrombin G20210A genotyping during thrombophilia workups after deep vein thrombosis, pulmonary embolism, unusual-site venous thrombosis, strong family history, or when hormone therapy decisions need inherited risk context. standard clinical references Genetics notes it is the second most common inherited thrombophilia in populations of European ancestry.

Heterozygous carriers (one copy) have moderately increased lifetime VTE risk; homozygous carriers (two copies) are rare but carry higher risk. GeneReviews emphasizes that many individuals with the variant never develop thrombosis, while acquired risks — obesity, surgery, smoking, pregnancy, and estrogen-containing contraceptives or HRT — stack with genotype. Co-inheritance with factor V Leiden substantially increases VTE risk. ASH 2023 guidelines support selective thrombophilia testing when results would change management.

Clinical Nursing Focus

Before collection, verify the indication matches institutional thrombophilia criteria, document personal and family VTE history, and confirm counseling when required. After results, teach that genetics informs long-term risk and prevention planning — it does not replace acute pathways for leg swelling, chest pain, or shortness of breath. Escalate acute symptoms according to facility policy while send-out genetics is pending.

Prothrombin G20210A Result Communication and VTE Safety

Prothrombin G20210A results change long-term thrombosis conversations for patients and families. Treating heterozygosity as an active clot — or dismissing homozygosity before hormone review — can cause delayed VTE care or unsafe estrogen exposure. Nurses protect patients with accurate risk language, acute symptom teaching, and timely specialist follow-up.

Highest-risk scenarios
  • Acute leg swelling or chest pain deferred because genetics is pending
  • Homozygous G20210A with estrogen contraceptive or HRT started without haematology review
  • Patient told a positive prothrombin gene confirms active PE or DVT today
  • Positive result communicated without thrombophilia follow-up or family screening plan

Document: indication, counseling status, family VTE history, specimen details, zygosity, hormone therapy, notifications, acute symptom teaching, and haematology/genetics referral.

What Prothrombin G20210A Testing Can and Cannot Tell You

This test can help identify:

  • Inherited prothrombin G20210A (F2) variant when appropriately ordered
  • Heterozygous vs homozygous carrier status to inform lifetime VTE risk discussions
  • Relatives at risk when cascade testing is offered per haematology or genetics protocol
  • Need for combined review of hormones, pregnancy, surgery prophylaxis, and anticoagulation duration — especially with factor V Leiden co-inheritance

This test cannot:

  • Diagnose acute deep vein thrombosis or pulmonary embolism by itself — use acute VTE pathways
  • Replace clinical assessment, Wells score, D-dimer, or imaging where indicated
  • Rule out all thrombophilia when negative — other genes and acquired causes may remain
  • Determine anticoagulation duration or hormone choices alone — requires specialist decisions

Pre-test Checks Before Prothrombin Genotyping

Verify

✓Correct patient, F2 G20210A order, and thrombophilia indication
✓DNA genotyping matches clinical question (not acute VTE rule-out alone)
✓Personal and family VTE history documented
✓Counseling or genetics referral completed when required
✓No active VTE symptoms requiring immediate escalation
✓Specimen type matches order (blood vs saliva kit)

Clarify before proceeding when:

  • Order is routine on acute admission without thrombophilia criteria
  • Patient has unilateral leg swelling, chest pain, or dyspnoea today
  • Counseling or consent missing when results affect family and hormone decisions
  • Estrogen therapy ordered without haematology input in known homozygous carrier
  • Known familial G20210A exists but generic screening without targeted testing is ordered
  • Saliva kit instructions not reviewed (eating, rinsing, labeling)
  • Team plans to defer acute VTE workup until genetics returns

Heterozygous vs Homozygous F2 Results and VTE Context

Pair prothrombin G20210A zygosity with hormone exposure, pregnancy plans, surgery, immobility, obesity, smoking, and concurrent thrombophilia results — particularly factor V Leiden co-inheritance. Heterozygous carriers have moderate lifetime risk; homozygous carriers have higher risk — yet many mutation carriers never develop clots.

Clinical contextPair with G20210ANursing focus
Heterozygous, no acute symptomsPositive G20210A, one copyBalanced risk teaching; haematology follow-up; family screening per protocol
Homozygous carrierTwo copies of variantUrgent specialist review; scrutinize estrogen and surgery prophylaxis plans
G20210A plus factor V LeidenDual inherited thrombophiliaEscalate combined-risk counseling; do not minimize with single-gene teaching
New leg swelling during testing waitAny genetic statusEscalate acute VTE pathway — do not wait for molecular results

On a small screen, swipe or scroll sideways to see the full table.

Thrombophilia Tests That Pair With Prothrombin G20210A

Related testWhy it may be ordered
Factor V Leiden genotypingMost common co-inherited thrombophilia marker screened in the same panel
Protein C and protein S activityNatural anticoagulant deficiency evaluation alongside inherited thrombophilia
Antithrombin activity and antigenHigher-risk thrombophilia component when activity is low on appropriately timed samples
Lupus anticoagulant / antiphospholipid panelAcquired antiphospholipid thrombophilia evaluation
Prothrombin time / INRFunctional coagulation monitoring when warfarin follows VTE treatment — distinct from G20210A genotyping

On a small screen, swipe or scroll sideways to see the full table.

Elevated Prothrombin Risk vs Active Clot Language

Bedside pointNursing note
Risk vs diagnosisNever chart that genetics alone confirms active DVT or PE
Dual variantsDocument factor V Leiden and G20210A together — combined risk exceeds either alone
Not a stat VTE testSend-out DNA does not rule in or out PE today — escalate symptoms clinically
Estrogen trapDocument combined oral contraceptives and HRT — carriers need specialist hormone counseling
Family conversationsCascade screening needs counseling; avoid pressuring relatives at the bedside
Panel contextInterpret G20210A with protein C/S, lupus anticoagulant, and factor V Leiden when ordered

On a small screen, swipe or scroll sideways to see the full table.

The clarify / hold rule

Clarify before proceeding when:

  • Indication does not match institutional thrombophilia criteria
  • Acute VTE symptoms are present or worsening
  • Counseling or consent is incomplete for a test affecting family and hormones
  • Homozygous G20210A on chart but estrogen therapy is newly ordered
  • Patient cannot describe acute symptoms that require urgent reporting
  • Saliva kit or blood specimen labeling mismatch
  • Positive result has no haematology or genetics follow-up scheduled

Prothrombin G20210A in Thrombophilia Pathways

Diagnostic safety badge: Routine diagnostic test — standard identification, preparation, and result-follow-up checks still apply; positive genetics may require specialist follow-up and family counseling.

Check-before-test protocol

  1. Identity + indication + thrombophilia criteria
  2. Family VTE and hormone history documented
  3. Counseling or consent when required
  4. Acute VTE symptom screen
  5. Correct specimen collection and labeling

Critical teach-back questions

  • “Can you tell me why we are checking for prothrombin G20210A?”
  • “What is the difference between a positive gene result and having a clot right now?”
  • “What leg or chest symptoms should you report before the result comes back?”

Care coordination: prescriber, haematology, genetics counselor, laboratory, anticoagulation clinic, obstetrics when relevant, and rapid response per institutional protocol.

Prothrombin G20210A Testing Quick Safety Checklist

  • Does this order meet thrombophilia testing criteria?
  • Did I teach acute VTE symptoms independent of pending genetics?
  • Is zygosity documented and routed to the right specialist?
  • Are factor V Leiden and estrogen plans reviewed for dual-variant or homozygous carriers?
  • Who must be notified about a positive or unexpected result?

Why Prothrombin Gene Mutation (G20210A) is Ordered

Prothrombin G20210A testing is ordered when clinicians need to assess inherited thrombophilia as part of a hypercoagulability evaluation — typically when results may influence anticoagulation duration, prophylaxis, hormone counseling, or family screening.

Clinical Indication What the Test Answers Nursing Rationale
Recurrent or unexplained venous thromboembolism Does an inherited thrombophilia change long-term management? Selective thrombophilia testing may be appropriate when results would alter anticoagulation or prophylaxis decisions per ASH 2023 and institutional pathways.
First VTE at young age, unusual site, or strong family history of prothrombin G20210A Should this common moderate-risk thrombophilia be identified? GeneReviews notes relative DVT risk is two- to fivefold increased in heterozygous adults; family history may prompt cascade testing when results could change hormone or prophylaxis choices.
Preconception or contraception counseling with personal/family thrombosis history Will genotype affect estrogen exposure or pregnancy planning? standard clinical references Genetics and GeneReviews note estrogen therapy and pregnancy increase risk in carriers; genetics or haematology interprets combined risk.
Thrombophilia panel after provoked or unprovoked VTE when results may change care Is F2 G20210A part of the ordered inherited thrombophilia panel? Often screened with factor V Leiden, protein C/S, antithrombin, and lupus anticoagulant when a full hypercoagulability evaluation is clinically indicated.
↔ On a small screen, swipe or scroll sideways to see the full table.

Contraindications and Precautions

There is no absolute contraindication to DNA collection itself. Testing may be inappropriate during acute thrombosis workup when immediate management will not change, or without counseling when results affect family members and hormone decisions.

When genetics must not delay acute VTE care
  • New unilateral leg swelling, pain, warmth, or redness — initiate VTE pathway per prescriber; do not wait for prothrombin G20210A results.
  • Acute chest pain, pleuritic pain, dyspnoea, tachycardia, or hypoxia suggesting PE.
  • Telling a patient with VTE symptoms that a negative pending genetic test rules out clot.
Interpretation pitfalls
  • Positive heterozygous result — moderate lifetime risk; many carriers never clot.
  • Homozygous result — higher risk; still requires clinical context and specialist plan.
  • Negative DNA test does not exclude all thrombophilia — lupus anticoagulant, antiphospholipid syndrome, and acquired causes may still be present.
Escalate If
  • Acute VTE signs or symptoms while genetics pending — escalate per facility policy.
  • Homozygous G20210A with new estrogen prescription — notify prescriber/haematology before administration when policy requires.
  • Positive result without documented follow-up for anticoagulation or family counseling plan.

Patient Preparation

Preparation focuses on order verification, family history, counseling when required, and correct specimen labeling — not fasting for standard germline DNA blood draws unless combined tests require it.

Pre-test checks
✓Verify thrombophilia indication and that F2 G20210A genotyping matches the clinical question.
✓Document personal and family VTE history, pregnancy plans, and hormone use.
✓Confirm counseling or genetics referral completed when institutional policy requires.
✓Explain blood draw or saliva kit steps; clarify test measures inherited risk, not active clot.
✓Assess literacy, privacy, and interpreter needs for genetic information.
✓For saliva kits, review food, drink, and rinse restrictions per manufacturer instructions.
Medications to Review or Hold

Review estrogen-containing contraceptives, hormone replacement therapy, selective estrogen receptor modulators, and current anticoagulants (warfarin, direct oral anticoagulants). Do not stop prescribed medicines without prescriber authorization — document therapy for interpretation.

Performance — nursing procedure guide

This page is a Tests & Diagnostics guide for Prothrombin Gene Mutation (G20210A). It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).

How the test is performed

Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:

Venipuncture

Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.

Result follow-up at a glance

Nursing workflow on this page — from order to safe action on results:

1
Confirm indication & correct order
2
Coordinate performance per nursing procedure guide (see above)
3
Document pre-analytic preparation & timing
4
Review result with trend & clinical picture
5
Escalate critical or discordant findings
6
Document communication & patient teaching

Results and Interpretation

Results are typically reported as prothrombin G20210A detected (heterozygous or homozygous) or not detected on DNA testing. Some laboratories report elevated prothrombin antigen or activity alongside genotyping. Nurses record the classification reported and route interpretation to haematology or genetics — not independent changes to anticoagulation or hormones.

Reference Range Disclaimer

Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.

Result Range / Finding Clinical Meaning Nursing Action
Negative / not detected Prothrombin G20210A not detected / wild-type F2 No inherited prothrombin G20210A variant identified on the performed assay — does not exclude other thrombophilias or acquired hypercoagulability Interpret with full thrombophilia panel and clinical history; continue VTE prevention per risk factors
Equivocal / borderline Inconclusive or insufficient DNA — repeat per laboratory protocol Specimen quality, quantity, or assay failure — may reflect labeling error or technical limitation Hold bedside conclusions; coordinate recollection or repeat testing per laboratory instructions
Positive / elevated Prothrombin G20210A detected — heterozygous (one copy) Inherited elevated prothrombin with moderately increased lifetime VTE risk; risk rises with estrogen therapy, pregnancy, surgery, immobility, and factor V Leiden co-inheritance per GeneReviews Notify prescriber/haematology per protocol; support counseling on hormones, pregnancy, and family screening; teach acute VTE symptoms
Not applicable / below detection limit Prothrombin G20210A detected — homozygous (two copies) Substantially higher thrombosis risk than heterozygous state; homozygosity is rare — still not a diagnosis of active clot today Urgent haematology/genetics follow-up per protocol; review estrogen exposure and prophylaxis plans; document family cascade counseling referral
↔ On a small screen, swipe or scroll sideways to see the full table.

Acute VTE Urgency With Pending Prothrombin Genetics

Prothrombin G20210A is not reported as a numeric critical laboratory value. Clinical urgency is driven by acute thrombosis symptoms, homozygous results with high-risk exposures, and failure to communicate positive results to appropriate specialists.

Critical Finding Threshold / Value Immediate Action
Acute VTE symptoms with any genetic status Leg swelling, pain, chest pain, dyspnoea, tachycardia, or hypoxia Escalate according to facility policy — use acute VTE imaging and treatment pathways; do not defer for pending prothrombin G20210A genotyping
Homozygous G20210A with planned estrogen therapy Two copies of prothrombin G20210A; estrogen contraceptive or HRT ordered Notify prescriber and haematology/genetics before hormone administration per protocol
Positive genetics without specialist follow-up Heterozygous or homozygous result; no haematology or counseling appointment Coordinate follow-up and document notification; evaluate outcomes after management plan is set
↔ On a small screen, swipe or scroll sideways to see the full table.
Stop and Escalate

Escalate according to facility policy when the patient develops symptoms suggesting acute venous thromboembolism, when a homozygous result is paired with high-risk hormone exposure, or when positive genetics has not been communicated within the timeframe defined by your thrombophilia service.

Factors Affecting Results

Prothrombin G20210A interpretation depends on zygosity, acquired risks, co-inherited thrombophilia, and test method. Nurses prevent harm by avoiding single-result conclusions and documenting clinical context.

False Positives
  • Assuming positive genetics explains a current clot without imaging when pre-test probability is low
  • Sample mix-up or mislabeling — rare but high-impact; always verify identifiers
  • Elevated prothrombin activity from acute illness misread as confirming genotype without DNA
False Negatives
  • DNA negative while other thrombophilias present — e.g., factor V Leiden or lupus anticoagulant
  • Testing only prothrombin G20210A when a broader thrombophilia panel was clinically indicated
  • Reassuring patient with strong symptoms because genetics is negative
Interfering Factors
  • Co-inherited factor V Leiden — combined risk exceeds either variant alone
  • Recent transfusion or transplant — may affect blood DNA source
  • Incomplete family history leading to wrong test (screening vs familial variant testing)
Test Limitations

Prothrombin G20210A testing alone does not diagnose active DVT or PE and cannot replace clinical assessment, D-dimer, or imaging. ASH 2023 generally recommends against broad thrombophilia testing in many VTE scenarios when results will not change management. Negative results do not eliminate clot risk from acquired factors. Management should follow haematology and genetics guidance — not nursing interpretation alone.

Nursing Responsibilities

Nursing care emphasizes appropriate ordering support, accurate specimen handling, balanced risk communication, acute symptom monitoring, and coordination with haematology or genetics for hormone and family decisions.

Before the Test
✓Verify indication, F2 genotyping order, and counseling status.
✓Collect VTE and pregnancy history; document estrogen or hormone therapy.
✓Prepare blood tubes or saliva kit per laboratory instructions.
✓Screen for acute VTE symptoms — escalate clinically before collection if present.
During the Test
✓Maintain privacy during genetic discussions; use interpreter when needed.
✓Label specimens at bedside with two identifiers.
✓Monitor for vasovagal symptoms during phlebotomy when blood is used.
After the Test
✓Track pending results and ensure haematology/genetics follow-up is scheduled.
✓Teach acute VTE symptoms to report before results return.
✓Reinforce that positive genetics is risk information, not an active clot diagnosis.
✓Document result notification, referrals, and family screening teaching per protocol.

Documentation

Documentation should capture indication, family history, specimen details, result zygosity, notifications, and teaching without implying independent genetic diagnosis.

Example Nursing Note

“Prothrombin G20210A DNA specimen collected 11:20 — lavender EDTA tube, two identifiers verified, sent to molecular laboratory. Indication: prior provoked DVT age 29; brother heterozygous G20210A. Patient on no estrogen therapy; rivaroxaban completed 6 weeks ago. Genetics counseling completed Monday. Pending result; taught to report unilateral leg swelling, chest pain, or sudden breathlessness immediately.”

Key Documentation Points
  • Indication, F2 genotyping order, and counseling/consent status
  • Personal and family VTE history, hormone therapy, pregnancy status
  • Specimen type, collection time, labeling, and transport
  • Result (not detected, heterozygous, homozygous) with laboratory nomenclature
  • Prescriber/haematology notification and patient teaching provided
  • Family screening referral and follow-up appointment details

Patient and Family Education

Patients often equate a “clotting gene” with an immediate emergency. Use calm, accurate language: the test clarifies inherited risk to guide prevention and family conversations.

✓Explain the test looks for a change in the prothrombin gene that can increase blood clot risk over time.
✓Clarify many people with the gene never develop a clot; others do when risks combine.
✓Describe the blood draw or saliva collection and how genetic privacy is protected per policy.
✓Teach leg swelling, calf pain, chest pain, and sudden breathlessness as report-now symptoms.
✓Explain hormone and pregnancy decisions may involve specialists after results return.
✓Ask what questions they want answered at the haematology or genetics follow-up visit.
📚

Prothrombin Gene Mutation (G20210A) NCLEX practice questions

Practice NCLEX-style clinical judgment focused on Prothrombin Gene Mutation (G20210A) safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.

Select a tab to view orders, results, assessment, and nursing note details for this case.

  • Order: Prothrombin G20210A DNA genotyping — thrombophilia panel
  • Indication: 29-year-old with prior provoked DVT; brother heterozygous for prothrombin G20210A
  • Timing: Collected today — 6 weeks after completing anticoagulation per protocol
  • Related orders: Factor V Leiden, protein C, protein S, lupus anticoagulant screen per protocol
Question 1 — Priority action

After reviewing the case tabs, what is the nurse’s priority action for this stable patient with a new heterozygous prothrombin G20210A result?

Question 2 — Recognize cues

Which findings from the case tabs should prompt clarification or escalation? Select all that apply

Question 3 — Trend interpretation

Which trends or contexts should the nurse recognize as concerning?

Trend snapshot
No prior genetic testing; acute-phase D-dimer elevated during admission (resolved)

Select all that apply

Question 4 — Matrix judgment

Classify each situation for this thrombophilia patient:

Finding Expected — document and continue monitoring Requires follow-up — notify team / repeat test Urgent — immediate escalation
Stable patient, heterozygous G20210A, haematology visit scheduled
Sudden unilateral calf swelling and pleuritic chest pain tonight
Patient taught to report leg swelling but cannot name other VTE symptoms
Homozygous G20210A with estrogen HRT newly prescribed without haematology review

On a small screen, swipe or scroll sideways to see the full table.

Question 5 — Clinical judgment

The prescriber asks whether a heterozygous prothrombin G20210A result alone changes tonight’s nursing plan for this asymptomatic patient. What is the best nursing response?

Question 6 — Documentation (cloze)

Complete the priority documentation after today’s heterozygous prothrombin G20210A result:

The highest-priority documentation action is .

Question 7 — Workflow (ordered response)

After a heterozygous prothrombin G20210A result on a stable thrombophilia workup, rank nursing actions (1 = first).

  1. Notify prescriber or haematology with result, hormone history, and pending panel tests
  2. Document zygosity, acute VTE symptom teaching, and pending thrombophilia panel status
  3. Confirm haematology follow-up and cascade counseling referral per protocol
  4. Tell the patient the positive gene confirms active pulmonary embolism today
Question 8 — Evaluate outcomes

Haematology reviews the heterozygous G20210A result and reinforces VTE prevention. The patient later reports new unilateral calf swelling and mild dyspnoea. What is the best nursing action?

Answer key & rationale

Next step Timed NCLEX Next Gen–style scenarios on NurseOnShift

Frequently Asked Questions

FAQ

What is prothrombin G20210A thrombophilia?

It is a specific F2 gene change (G20210A) that increases prothrombin production, leading to more thrombin and a greater tendency to form abnormal clots. standard clinical references Genetics notes it is the second most common inherited thrombophilia in many populations of European ancestry.

Does a positive prothrombin G20210A result mean the patient has a clot now?

No. The test identifies inherited risk. GeneReviews emphasizes that many heterozygous or even homozygous carriers never develop thrombosis, and acute VTE requires clinical assessment and imaging — not genetics alone.

What is the difference between heterozygous and homozygous G20210A results?

Heterozygous means one copy of the variant (moderately increased lifetime VTE risk). Homozygous means two copies (higher risk; very uncommon). Exact management is set by haematology or genetics with the full clinical picture.

Should every patient with one DVT receive prothrombin G20210A testing?

Not routinely. ASH 2023 guidelines conditionally recommend against broad thrombophilia testing in many VTE scenarios and support selective testing when results would change management — such as strong family history or unusual presentations.

How does factor V Leiden interact with prothrombin G20210A?

Co-inheritance substantially increases VTE risk compared with either variant alone per GeneReviews and clinical reviews. When both are on a panel, nurses ensure results are communicated together to haematology — not interpreted in isolation at the bedside.

Is fasting required before prothrombin G20210A testing?

Usually no special preparation is required for DNA blood draws. Saliva kits have specific restrictions — follow the kit and laboratory instructions. Fast only if other tests on the same draw require it.

When should nurses escalate before genetic results return?

Escalate according to facility policy if the patient develops new unilateral leg swelling, pain, warmth, redness, chest pain, dyspnoea, tachycardia, or hypoxia — these may indicate acute VTE regardless of pending prothrombin G20210A results.

References

References
  1. U.S. National Library of Medicine. Prothrombin thrombophilia. MedlinePlus Genetics.
    https://medlineplus.gov/genetics/condition/prothrombin-thrombophilia/
  2. Rosendaal FR; et al. Prothrombin Thrombophilia. GeneReviews. NIH Bookshelf; updated 2018.
    https://www.ncbi.nlm.nih.gov/books/NBK1148/
  3. American Society of Hematology. 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC10709681/
  4. McGlennen RC; Key NS. Clinical and laboratory management of the prothrombin G20210A mutation. Arch Pathol Lab Med. 2002.
    https://pubmed.ncbi.nlm.nih.gov/12421141/
  5. Segal JB; Brotman DJ; Necochea AJ; et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism. JAMA. 2009.
    https://pubmed.ncbi.nlm.nih.gov/19531785/
  6. Poort SR; Rosendaal FR; Reitsma PH; Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996.
    https://pubmed.ncbi.nlm.nih.gov/8639126/
  7. National Library of Medicine. Genetic Testing Registry: Thrombophilia due to prothrombin G20210A variant. NIH.
    https://www.ncbi.nlm.nih.gov/gtr/tests/5169/
  8. Centers for Disease Control and Prevention. Venous thromboembolism (blood clots): data and statistics. CDC.
    https://www.cdc.gov/ncbddd/dvt/data.html

Related Topics

Specimen Collection

Broader specimen-handling skills for genetic and laboratory testing

Nursing procedure

Protein S

Natural anticoagulant often evaluated in the same hypercoagulability panel

Test / Diagnostic

Antithrombin III

Higher-risk thrombophilia marker in comprehensive panels

Test / Diagnostic

INR

Monitoring test when warfarin follows VTE treatment

Test / Diagnostic

Heparin

Acute anticoagulation often used before long-term VTE therapy

Medication

Miscarriage

May prompt specialist-directed thrombophilia evaluation

Condition

Editorial Standards & Medical Review

About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.

Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Prothrombin Gene Mutation (G20210A).

Policies: Medical Review Process · Editorial Policy · Correction Policy

Evidence-based nursing education and clinical resources

Disclaimer: This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range. Content written by a Registered Nurse and medically reviewed by Dr. Adam Sayedi, MD. Last reviewed: June 20, 2026.